

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or a pharmaceutically acceptable salt thereof and administering an effective amount of gemcitabine.
2. (previously presented) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt thereof and administering an effective amount of gemcitabine in a potentiating ratio.
3. (previously presented) The method according to claim 1 or claim 2, wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are administered concomitantly.
4. (previously presented) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt thereof and administering an effective amount of gemcitabine, wherein the DMXAA or pharmaceutically acceptable salt thereof and the gemcitabine are administered sequentially.
5. (cancelled)
6. (cancelled)
7. (previously presented) A composition comprising a combination of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine.

8. (previously presented) The composition according to claim 7 wherein the DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine are present in a potentiating ratio.

9. (cancelled)

10. (cancelled)

11. (previously presented) A pharmaceutical formulation comprising a combination of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine in association with one or more pharmaceutically acceptable carriers therefor.

12. (original) A pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.

13. (previously presented) The pharmaceutical formulation according to claim 11 or 12 wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are present in a potentiating ratio.

14. (cancelled)

15. (cancelled)

16. (previously presented) A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine with one or more pharmaceutically acceptable carriers therefor.

17. (previously presented) The process according to claim 16 wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are present in a potentiating ratio.

18. (cancelled)

19. (cancelled)
20. (previously presented) A kit comprising in association for separate administration DMXAA or a pharmaceutically acceptable salt thereof and gemcitabine.
21. (previously presented) The kit according to claim 20 wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are present in a potentiating ratio.
22. (cancelled)
23. (cancelled)
24. (cancelled)
25. (cancelled)
26. (cancelled)
27. (cancelled)

[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]